Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01878708
Other study ID # 13-165
Secondary ID
Status Terminated
Phase Early Phase 1
First received May 23, 2013
Last updated March 2, 2017
Start date July 2013
Est. completion date February 2017

Study information

Verified date March 2017
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.


Description:

This is an open-label, investigator-initiated, single-arm pilot study. Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) will receive Oncaspar® every 3 weeks up to a maximum of 8 courses or until disease progression or unacceptable toxicity. They will also receive dexamethasone 40mg daily for 4 days with every cycle. They will be restaged after 2 courses (6 weeks) and after 8 courses (24 weeks).

Both Oncaspar and dexamethasone have been used together to treat ALL and ENKTL, which is another subtype of T cell lymphoma. The combination may provide a collaborative attack against the cancer cell; moreover, the dexamethasone could also prevent some of the side effects of Oncaspar; especially allergic reactions. This study will test these two drugs together to determine if they are an effective treatment for T-Cell Lymphoma. Each drug is commercially available to the drug market.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients must meet the following criteria on screening examination to be eligible to participate in the study:

- Patients must have histologically confirmed peripheral T-cell lymphoma, with the diagnostic specimen reviewed at one of the DFHCC hematopathology laboratories. Eligible histologies include:

- PTCL-NOS

- Systemic T cell/null anaplastic large cell lymphoma (ALCL), regardless of Alk status

- Angioimmunoblastic T-cell lymphoma (AITL)

- Hepatosplenic (alpha-beta or gamma-delta) lymphoma (HSL)

- Enteropathy-associated T-cell lymphoma (EATL)

- Adult T-cell leukemia/lymphoma (ATLL), lymphomatous subtype

- Subcutaneous panniculitis-like T-cell lymphoma

- T-cell Prolymphocytic Leukemia (T-PLL)

- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan

- Patients must have relapsed or progressed after at least 1 prior course of anti-lymphoma therapy.

- Age 18-65 years.

- ECOG performance status <2 (see Appendix A).

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study.

- Patients with cutaneous disease only are not eligible.

- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier to grade 1 or below (unless approved by the Study Chair).

- Patients may not be receiving any other study agents at the time of first treatment.

- History of treatment with an asparaginase agent.

- Patients with a history of alcohol abuse, or patients unwilling or unable to remain completely abstinent of alcohol during the study period.

- Hepatitis B or C seropositivity (except for hepatitis B with negative surface antigen and hepatitis B viral load).

- Total bilirubin > institutional upper limit of normal (ULN), unless due to hemolysis or Gilbert's disease).

- AST/ALT = 3 x ULN.

- History of pancreatitis, or amylase > ULN or lipase > ULN.

- History of thromboembolic disease.

- Grade 2 or above neuropathy.

- Diabetes mellitus, unless it is type II diabetes adequately controlled with anti-diabetic agents (A1c < 7).

- History of CNS hemorrhage or thrombosis. Patients with a history of CNS lymphomatous involvement are eligible only if their CNS disease is in remission at the time of study entry.

- Uncontrolled intercurrent illness including, but not limited to uncontrolled active infection, symptomatic congestive heart failure (New York Hospital Association (NYHA) class II-IV, resulting in at least slight limitation of activity), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Inability to provide informed consent

- Pregnancy or lactation.

- Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.

- HIV-positive individuals on combination antiretroviral therapy are ineligible.

Study Design


Intervention

Drug:
PEG-L-asparaginase

Dexamethasone acetate
-dexamethasone 40mg daily for 4 days with every cycle.

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute Sigma Tau Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate (complete + partial response) in evaluable patients. 24 weeks
Secondary Duration of response for patients with PR or CR 24 weeks
Secondary Grade 2 and above attributable toxicity of treatment. 24 weeks
Secondary Progression-free survival. This will be assessed in both evaluable patients and in responders. 1 year
Secondary Complete remission (CR) rate. This will be assessed both in the intent-to-treat and in the evaluable populations. 24 weeks
Secondary Partial remission (PR) rate. This will be assessed both in the intent-to-treat and in the evaluable populations. 24 weeks
Secondary The stable disease (SD) rates in this population and in the intent-to-treat population 24 weeks
Secondary Progressive disease (PD) rate. This will be assessed both in the intent-to-treat and in the evaluable populations. 24 weeks
Secondary Stable disease (SD) rate. This will be assessed both in the intent-to-treat and in the evaluable populations. 24 weeks
Secondary Overall survival This will be assessed in both evaluable patients and in responders. 1 year
See also
  Status Clinical Trial Phase
Completed NCT00959686 - Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma Phase 2
Active, not recruiting NCT04712864 - Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma Phase 1
Recruiting NCT05665530 - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies Phase 1
Completed NCT01941680 - High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Recruiting NCT05075460 - Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma Phase 3
Completed NCT03734601 - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Phase 2
Completed NCT02017613 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Phase 1
Enrolling by invitation NCT01854112 - Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma N/A
Completed NCT01553786 - Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) Phase 2
Completed NCT00542919 - A Study for Patients With Non-Hodgkin's Lymphomas Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Active, not recruiting NCT03952078 - A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Phase 1
Not yet recruiting NCT05387226 - Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma Phase 1
Completed NCT02424045 - Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Phase 2
Completed NCT01871675 - Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Phase 1
Terminated NCT00893516 - CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Phase 2
Completed NCT01902225 - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT02086591 - A Phase II Study of Doxycycline in Relapsed NHL Phase 2
Recruiting NCT04264078 - Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Early Phase 1
Completed NCT00001582 - Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer